- Previous Close
327.87 - Open
317.62 - Bid 329.92 x 100
- Ask 332.94 x 100
- Day's Range
310.00 - 333.00 - 52 Week Range
189.00 - 377.46 - Volume
304,228 - Avg. Volume
405,835 - Market Cap (intraday)
7.314B - Beta (5Y Monthly) -0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-21.90 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
414.07
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
www.madrigalpharma.comRecent News: MDGL
View More
Performance Overview: MDGL
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDGL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDGL
View MoreValuation Measures
Market Cap
7.24B
Enterprise Value
6.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
38.72
Price/Book (mrq)
9.60
Enterprise Value/Revenue
35.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-258.64%
Return on Assets (ttm)
-36.98%
Return on Equity (ttm)
-80.35%
Revenue (ttm)
180.13M
Net Income Avi to Common (ttm)
-465.89M
Diluted EPS (ttm)
-21.90
Balance Sheet and Cash Flow
Total Cash (mrq)
926.25M
Total Debt/Equity (mrq)
15.85%
Levered Free Cash Flow (ttm)
-296.99M